SureTrader
Home > Boards > US Listed > Biotechs >

Protagonist Therapeutics Inc (PTGX)

PTGX RSS Feed
Add PTGX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/22/2016 1:31:40 PM - Followers: 3 - Board type: Free - Posts Today: 0

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist's primary focus is on developing oral peptide drugs that specifically target biological pathways. Its oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company's initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn's disease (CD). Protagonist's product candidate beyond IBD is PTG-300, which is an injectable hepcidin mimetic peptide that the Company is developing for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD).
SureTrader
PTGX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PTGX News: Statement of Changes in Beneficial Ownership (4) 01/17/2018 04:35:46 PM
PTGX News: Current Report Filing (8-k) 01/08/2018 06:09:42 AM
PTGX News: Statement of Changes in Beneficial Ownership (4) 01/04/2018 09:02:40 AM
PTGX News: Amended Statement of Ownership (sc 13g/a) 01/04/2018 09:01:20 AM
PTGX News: Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 01/04/2018 08:00:00 AM